Healthcare Industry News:  Meniscus Implant 

Devices Regenerative Medicine Orthopaedic

 News Release - December 5, 2007

ReGen Biologics Introduces New Brand Name and Websites

HACKENSACK, N.J.--(HSMN NewsFeed)--ReGen Biologics (OTC: RGBI ) today announced the international release of a new brand name – MenaflexTM – for its collagen Meniscus Implant device and associated product web site, “The CMI® name was used during the research and development phase of the Company’s collagen Meniscus Implant device, and it will continue to be seen in numerous scientific publications and clinical references. Now that we are marketing the product outside the United States, we will utilize a unique brand name that allows for improved recognition among patients and surgeons,” stated Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer.

To advance international awareness and understanding of the Menaflex product and the associated surgical procedure, the Company is launching which provides a wealth of information regarding knee and meniscus injuries and treatment options, including the Menaflex procedure. The website was designed specifically for patients around the world, and it incorporates local country directories of surgeons trained in the Menaflex procedure, from which potential patients can seek additional information and a specific diagnosis.

The full transition to the Menaflex name will take approximately three quarters as the Company works through current levels of inventory on product and collateral materials.

Simultaneously with the launch of, the Company has updated its corporate website (, which provides a comprehensive overview of the Company and its technology, while also serving as an excellent investor resource. Dr. Bisbee commented, “Patients, surgeons and investors from around the world who are interested in our Company and products can find the specific product information for their locale and general information regarding ReGen Biologics.”

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. ReGen’s first approved product using its collagen scaffold technology is the Menaflex™ meniscus application, which is cleared for sale in Europe and other countries and marketed through ReGen’s European subsidiary, ReGen Biologics AG. ReGen continues to work to obtain FDA clearance of the Menaflex device in the United States.

ReGen has conducted the largest human clinical trial on an arthroscopic meniscus procedure and the resulting database has unique value in better understanding meniscus injuries. The Company is headquartered in Hackensack, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA. For more information on ReGen, visit .

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2006 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at, from commercial document-retrieval services and at the Web site maintained by the SEC at .

Source: ReGen Biologics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.